Sang-Cheol Bae1, Young Ho Lee2. 1. Department of Rheumatology, Hospital for Rheumatic Diseases, Division of Rheumatology, Hanyang University, Hanyang, Korea (Republic of). 2. Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, 136-705, Seoul, Seongbuk-gu, Korea (Republic of). lyhcgh@korea.ac.kr.
Abstract
OBJECTIVE: The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). METHODS: We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RA patients. RESULTS: A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682-1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281-1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTX toxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTX toxicity in all genetic models. CONCLUSIONS: This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RA patients.
OBJECTIVE: The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). METHODS: We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RApatients. RESULTS: A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682-1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281-1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTXtoxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTXtoxicity in all genetic models. CONCLUSIONS: This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RApatients.
Authors: R Takatori; K A Takahashi; D Tokunaga; T Hojo; M Fujioka; T Asano; T Hirata; Y Kawahito; Y Satomi; H Nishino; T Tanaka; Y Hirota; T Kubo Journal: Clin Exp Rheumatol Date: 2006 Sep-Oct Impact factor: 4.473
Authors: Debabrata Banerjee; Philipp Mayer-Kuckuk; Gina Capiaux; Tulin Budak-Alpdogan; Richard Gorlick; Joseph R Bertino Journal: Biochim Biophys Acta Date: 2002-07-18